startupsConnecta raises €3.1M for Fragile X syndrome Phase 2The Barcelona-based biotech will use the financing to complete a 30-patient Phase 2a study of its lead candidate CTH120, with the first efficacy data expected in mid-2027. more ➔
clinical dataTeitur Trophics reports positive phase 1 data for Parkinson’s peptideDanish biotech Teitur Trophics completed its phase 1 study and said its experimental Parkinson’s disease treatment TT-P34 was safe and reached the central nervous system, supporting plans to move the … more ➔
M&ALeyden Labs reveals RIGImmune acquisition with Phase 1 dataDutch biotech Leyden Labs has reported positive Phase 1 results for intranasal RIG-101 and disclosed that it acquired the drug’s developer, RIGImmune, earlier this year. more ➔
Drug deliveryInside exosomes: Nature’s drug carriersNext-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have revolutionized medicine. Yet, the main hurdle remains targeted delivery: avoiding … more ➔
clinical dataPharvaris oral HAE drug cuts attacks by 83% in Phase 3Switzerland-based Pharvaris’ once-daily oral deucrictibant XR reduced hereditary angioedema (HAE) attacks by 83% versus placebo in a pivotal Phase 3 trial, putting the experimental prophylactic into … more ➔
clinical dataNovartis’ $12B Avidity bet suffers Phase 3 blowNovartis has suffered another pipeline setback after del-desiran, an antibody-oligonucleotide conjugate acquired with Avidity Biosciences, failed to significantly improve hand function over placebo in … more ➔
financeGermany’s NRW state bets €200M on AI-powered cancer researchNorth Rhine-Westphalia (NRW), a state located in the North-West of Germany, is investing €200 million to connect university hospitals in Aachen, Bochum, Bonn, Düsseldorf, Essen, Cologne and Münster, … more ➔
startupsVaxdyn raises €11M Series A to test AMR vaccineSpanish biotech Vaxdyn has raised an €11 million Series A to take K-VAX, its vaccine against Klebsiella pneumoniae and Acinetobacter baumannii, into a first-in-human Phase 1 trial. Portuguese investor … more ➔
startupsBioInnovation Institute backs six startups with €8MCopenhagen’s BioInnovation Institute (BII) is providing six early-stage companies with €1.3 million each in convertible loans, taking its total financing of each startup to €1.8 million. more ➔
clinical dataNovartis’ Lp(a) drug misses Phase 3 endpointNovartis’ pelacarsen failed to reduce cardiovascular events in the first Phase 3 outcomes trial of an Lp(a)-lowering drug, despite successfully lowering the genetically driven cardiovascular risk … more ➔
